المؤلفون: 黃聖懿, Huang, Shang-Yi

المساهمون: 許世明, 田蕙芬, 臺灣大學：

مصطلحات موضوعية: 多發性骨髓瘤, 流行病學, 台灣, 細胞遺傳學, 動物模式, multiple myeloma, epidemiology, Taiwan, cytogenetics, animal model

وصف الملف: 6857064 bytes; application/pdf

العلاقة: Ahmann GJ, Jalal SM, Juneau AL, et al. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet 1998;101:7-11. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994;330:484-489. Alexanian R, Dimopoulos MA. Management of multiple myeloma. Semin Hematol 1995;32:20-30. Anagnostopoulos A, Gika D, Symeonidis A, et al. Multiple myeloma in elderly patients: prognostic factors and outcome. Eu J Haematol 2005;75:370-375. Anderson KC, Palumbo A. Multiple Myeloma Research Foundation. Treatment options for older myeloma patients. From the Multiple Myeloma Research Foundation. Oncology (Huntington) 2005;19:447-450. Ashmann EMJ, van Tol MDJ, Oudemann-Gruber J, et al. The SCID mouse as a model for multiple myeloma. Brit J Haematol 1995;89:319-327. Avet-Loiseau H, Facon T, Grosbois B, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002;99:2185-2191. Bakkus MH, Van Riet I, Van Camp B et al. Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B-cell. Br J Haematol 1994;87:68-74. Barille S, Akhoundi C, Collette M, et al. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMp-2, and induction of MMP-1 by myeloma cells. Blood 1997;90:1649-1655. Baris D, Brown LM, Silverman DT, et al. Socioeconomic status and multiple myeloma among US blacks and whites. American Journal of Public Health 2000;90:1277-1281. Baris D, Silverman DT, Brown LM, et al. Occupation, pesticide exposure and risk of multiple myeloma. Scand J Work Environ Health 2004;30:215-222. Barlogie B: Plasma cell myeloma, in Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U (eds): William’s Textbook of Hematology. New York, NY, McGraw Hill, 2001, p1279-1304. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood 2004;103:20-32. Bartlett JB, Tozer A, Stirling D, Zeldis JB. Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. Br J Cancer 2005;93:613-619. Benjamin M, Reddy S, Brawley OW. Myeloma and race: A review of the literature. Cancer and Metastasis Reviews 2003;22:87-93. Berenson JR, Wong R, Kim K, et al. Evidence for peripheral blood B lymphocyte but not T lymphocyte involvement in multiple myeloma. Blood 1987;70:1550-1553. Berenson JR, Vescio RA, Said J. Multiple myeloma: the cells of origin- A two-way street. Leukemia 1998;12:121-127. Bergsagel DE, Bergsagel PL. Epidemiology and etiology of plasma cell neoplasms. In: Gahrton, G., Durie, B.G.M., Samson, D.M. (eds) Multiple myeloma and related disorders. 2004. London: Arnold, pp:15-45. Bergsagel PL, Chesi M, Nardini E, et al. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Nat Acad Sci USA 1996;93:13931-13936. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene 2001;20:5611-5622. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005;23:6333-6338. Bertazzi A, Pesatori AC, Consonni D, et al. Cancer incidence in a population accidentally exposed to 2,3,7,8-tetrachlorodibenzo-para-dioxin. Epidemiology 1993;4:398-406. Bhatia KG, Cherney BW, Huppi K, et al. A deletion linked to a poly(ADP-ribose) polymerase gene on chromosome 13q33-qter occurs frequently in the normal black population as well as in multiple tumor DNA. Cancer Res 1990;50:5406-5413. Billadeau D, Blackstadt M, Greipp P, et al. Analysis of B-lymphocyte malignancies using allele-specific polymerase chain reaction: A technique for sequential quantitation of residual disease. Blood 1991;78:3021-3029. Billadeau D, Ahmann G, Greipp P, et al. The bone marrow of multiple myeloma patients contains B cell populations a different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 1993;178:1023-1031. Blade J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol 1994;12:2398-2404. Blade J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematology 1996a;93:345-351. Blade J, Kyle RA, Greipp PR. Multiple myeloma in patients younger than 30 years. Arch Intern Med 1996b;156:1463-1468. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115-1123. Blair A, Zahm SH, Pearce NE, et al Clues to cancer etiology from studies of farmers. Scand J Work Environ Health 1992;18:209-215. Broccia G, Deplano W, VI PD, et al. Hematological malignancies in the island of Sardinia, 1974-1993: age and sex distributions and temporal changes in incidence. Hematol Oncol 2004;22:91-109. Brown LM, Pottern LM, Silverman DT, et al. Multiple myeloma among blacks and whites in the United States: role of cigarettes and alcoholic beverages. Cancer Causes Control 1997;8:610-614. Brown LM, Linet MS, Greenberg RS, et al. Multiple myeloma and family history of cancer among blacks and whites in the U.S. Cancer 1999;85:2385-2390. Brown LM, Gridley G, Pottern LM, et al. Diet and nutrition as risk factors for multiple myeloma among blacks and whites in the United States. Cancer Causes and Control 2001;12:117-125. Boice JD Jr, Day NE, Andersen A, et al. Second cancers following radiation treatment for cervical cancer. An international collaboration among cancer registries. J Natl Cancer Inst 1985;74:955-975. Bourguet CC, Grufferman S, Delzell E, et al. Multiple myeloma and family history of cancer. A case-control study. Cancer 1985;56:2133-2139. Burnett C, Robinson C, Walker J. Cancer mortality in health and science technicians. Am J Ind Med 1999;36:155-158. Calasanz MJ, Cigudosa JC, Odero MD, et al. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations. Genes Chromosom Cancer 1997a;18:84-93. Calasanz MJ, Cigudosa JC, Odero MD, et al. Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma. Br J Haematol 1997b;98:418-425. Cannon MJ, Pisa P, Fox RI, et al. Epstein-Barr virus induces aggressive lymphoproliferative disorders of human B cell origin in SCID/hu chimeric mice. J Clin Invest 1990;85:1333-1337. Cavo M, Zamagni E, Tosi P, et al. Bologna 2002 study. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005;106:35-39. Cao J, Hong CH, Rosen L, et al. Deletion of genetic material from poly (ADP-ribose) polymerase-like gene on chromosome 13 occurs frequently in patients with monoclonal gammopathies. Cancer Epidemiol Biomarks Prev 1995;4:759-763. Cao K, Hollenbach J, Shi X, et al. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Human Immunology 2001;62:1009-1030. Cartwright RA, Gurney KA, Moorman AV. Sex ratios and the risks of haematological malignancies. Br J Haematol 2002;118:1071-1077. Chauhan D, Hideshima T, Mitsiades C, et al. Proteasome inhibitor therapy in multiple myeloma. Molecular Cancer Therapeutics 2005;4:686-692. Chen BJ, Epstein J. Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells. Blood 1996;87:1972-1976. Chang H, Sloan S, Li D, et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004;125:64-68. Chen CY, Yao M, Tang JL, et al. Chromosomal abnormalities of 200 Chinese patients with non-Hodgkin’s lymphoma in Taiwan: with special reference to T-cell lymphoma. Ann Oncol 2004;15:1091-1096. Chesi M, Nardini E, Brents LA. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma: Association with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genet 1997;16:260-264. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-1883. Chng WJ, Van Wier SA, Ahmann GJ, et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 2005;106:2156-2161. Cigudosa JC, Rao PH, Calasanz MJ, et al. Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood 1998;91:3007-3010. Corey KM, Vena JE. Cancer differentials among US blacks and whites: quantitative estimates of socioeconomic-related risks. J Natl Med Assoc 1994;86:209-215. Corradini P, Boccadoro M, Voena C, et al. Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to Cm sequence in immunoglobulin (IgG)- and IgA- secreting multiple myeloma. J Exp Med 1993a;178:1091-1096. Corradini P, Ladeto M, Voena C, et al. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood 1993b;81:2708-2713. Corso A, Klersy C, Lazzarino M, et al. Multiple myeloma in younger patients: the role of age as prognostic factor. Annals of Hematology 1998;76:67-72. Crocetti E, Capocaccia R, Casella C, et al. Population-based incidence and mortality cancer trends (1986-1997) from the network of Italian cancer registries. Eu J Cancer Pre 2004;13:287-295. Croese JW, Vas Nunes CM, Radl J, et al. The 5T2 mouse multiple myeloma model: characterization of 5T2 cells within the bone marrow. Br J Cancer 1987;56:555-560. Cuzick J, De Stavola B. Multiple myeloma- a case-control study. Br J Cancer 1988;57:516-520. Damiano JS, Cress AE, Hazlehurst LA, et al. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93:1658-1667. Davis DL, Hoel D, Fox J, et al. International trends in cancer mortality in France, West Germany, Italy, Japan, England and Wales, and the United States. Annals New York Academy of Sciences 1991;609:5-48. De Lisi V. Leukemias and multiple myeloma. Epidemiol Prev 2004;28(2 Suppl):97-101. Devesa, SS. Descriptive epidemiology of multiple myeloma. In: Obrams, G.I., Potter, M. (eds) Epidemiology and biology of multiple myeloma. German: Springer-Verlag, 1991;pp:3-12. Debes-Marun CS, Dewald GW, Bryant S, et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003;17:427-436. Desikan R, Barlogie B, Sawyer J, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000;95:4008-4010. Dilber MS, abedi MR, Bjorkstrand B, et al. Suicide gene therapy for plasma cell tumors. Blood 1996;88:2192-2209. Dispenzieri A, Lacy MQ, Greipp PR. Multiple myeloma. In: Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader B, eds. Wintrobe’s clinical hematology. 2004. 11th/e, pp2584-2636. Dong C, Hemminki K. Second primary neoplasms among 53,149 haematolymphoporliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms. Br J Cancer 2001;85:997-1005. Drach J, Ackermann J, Fritz E, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998;92:802-809. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36:842-854. Durie BG.M. The epidemiology of multiple myeloma. Seminars in Hematology 2001;38 (2 suppl 3):1-5. Epstein J. Myeloma stem cell phenotype- Implications for treatment. Hematol Oncol Clin North Am 1997;11:43-49. Epstein J, Yaccoby S. The SCID-hu myeloma model. Methods in Molecular Medicine 2005;113:183-190. Fabris S, Agnelli L, Mattioli M, et al. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses. Genes, Chromosomes & Cancer 2005;42(2):117-127. Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001;97:1566-1571. Fassas AB, Spencer T, Sawyer J, et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 2002;118:1041-1047. Feinman R, Koury J, Thames M, et al. Role of NF-κB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 1999;93:3044-3052. Feo-Zuppardi J, Taylor CW, Iwato K. Long term engraftment of fresh human myeloma cells in SCID mice. Blood 1992;80:2843-2850. Fonseca R, Harrington D, Oken MM, et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (Δ13) in multiple myeloma: An Eastern Cooperative Oncology Group study. Cancer Res 2002;62:715-720. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res 2004;64:1546-1558. Friedman GD, Herrinton LJ. Obesity and multiple myeloma. Cancer Causes Control 1994;5:479-483. Fritschi L., Siemiatycki J. Lymphoma, myeloma and occupation: results of a case-control study. Int J Cancer 1996;67:498-503. Gado K, Silva S, Paloczi K, et al. Mouse plasmacytoma: an experimental model of human multiple myeloma. Haematologica 2001;86:227-236. Gallagher RP, Spinelli JJ, Elwood JM, et al. Allergies and agricultural exposures as risk factors for multiple myeloma. British Journal of Cancer 1983;48:852-857. Garand R, Avet-Loiseau H, Accard F, et al. t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia 2003;17:2032-2035. Georgii-Hemming P, Stromberg T, Janson ET, et al. The somatostatin analog octreotide inhibits growth of interleukin-6 (IL-6)-dependent and IL-6 independent human multiple myeloma cell lines. Blood 1999;93:1724-1731. Giuliani N, Colla S, Lazzaretti M, et al. Pro-angiogenetic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis. Blood 2003;102:638-645. Goto T, Kennel SJ, Abe M, et al. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 1994;84:1922-1930. Gozzetti A, Davis EM, Espinosa R 3rd, et al. Identification of novel cryptic translocations involving IGH in B-cell non-Hodgkin's lymphomas. Cancer Res 2002;62:5523-5527. Gramenzi A, Buttino I, Goodacre A, et al. Medical history and the risk of multiple myeloma. Br J Cancer 1991;63:769-772. Greenberg GN, Dement JM. Exposure assessment and gender differences. J Occup Med 1994;36:1187-1198. Greipp PR, San Miguel J, Durie BG, et al. International Staging System for multiple myeloma. J Clin Oncol 2005;23:3412-3420. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myelma: An overview of published trials. J Clin Oncol 1992;10:334-342. Grimwood J, Gordon LA, Olsen A, et al. The DNA sequence and biology of human chromosome 19. Nature 2004;428:529-535. Grulich AE, McCredie M, Coates M. Cancer incidence in Asian migrants to New South Wales, Australia. British Journal of Cancer 1995;71:400-408. Grigorieva I, Thomas X, Epstein J. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp Hematol 1998;26:597-603. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91:3-21. Harada H, Kawano MM, Huang N, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 1993;81:2658-2663. Harousseau JL. Stem cell transplantation in multiple myeloma (0, 1, or 2). Current Opinion in Oncology 2005;17:93-98. Harrison SJ, Cook G. Immunotherapy in multiple myeloma--possibility or probability? Br J Haematol 2005;130:344-362. Hazlehurst LA, Foley NE, Gleason-Guzman MC, et al. Multiple mechanisms confer resistance to mitoxantron in the human 8226 myeloma cell line. Can Res 1999;59:1021-1028. He J, Gu D, Wu X, et al. Major causes of death among men and women in China. N Engl J Med 2005;353:1124-1134. Health and Vital Statistics. Vol 1: General Health Statistics. Republic of China (R.O.C.), 2003. Hemminki K, Li X, Czene K. Familiar risk of cancer: data for clinical counseling and cancer genetics. Int J Cancer 2004;108:109-114. Herrinton LJ, Demers PA, Koepsell TD, et al. Epidemiology of the M-component immunoglobulin types of multiple myeloma. Cancer Causes Control 1993;4:83-92. Hideshima T, Chauhan D, Richardson P, Anderson KC. Identification and validation of novel therapeutic targets for multiple myeloma. J Clin Oncol 2005;23:6345-6350. Ho F, Lortan J, Khan M, et al. Distinct short-lived and long-lived antibody-producing cell populations. Eu J Immunol 1986;16:1297-1301. Hogan CJ, Shpall EJ, McNulty O, et al. Engraftment and development of human CD34+ enriched cells from umbilical cord blood in NOD/LtSz-scid/scid mice. Blood 1997;90:85-96. Hsu FJ, Benike C, Fagnoni F. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-58. Huang SY, Tang JL, Yao M, et al. Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma. Ann Hematol 2003;82:558-564. Huang SY, Tien HF, Su FS, Hsu SM. Non-irradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma- a potential in vivo culture system. Am J Pathol 2004;164:747-756. Huang SY, Tang JL, Jou ST, et al. Minimally differentiated acute myeloid leukemia in Taiwan: predominantly occurs in children less than 3 years and adults between 51 and 70 years. Leukemia 1999;13:1506-1512. Huang SY, Yao M, Tang JL, et al. Clinical significance of cytogenetics and interphase fluorescence in situ hybridization analysis in newly-diagnosed multiple myeloma in Taiwan. Ann Oncol 2005;16:1530-1538. Huang YW, Richardson JA, Tong AW, et al. Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease. Cancer Res 1993;53:1392-1396. Huang YW, Hamilton A, Arnuk OJ, et al. Current drug therapy for multiple myeloma. Drugs 1999;57:485-506. Iida S, Butler M, Rao P, et al. MUM1/ICSAT, a member of the interferon regulatory factor family (IRF) is involved in chromosomal translocations in multiple myeloma. Blood 1996;80:450a. International Labor Office. 1991. International Standard Classification of Occupations. Geneva: International Labor Office. Isabel dos Santos Silva. Chapter 4: Measures of occurrence of disease and other health-related events, in Cancer epidemiology: principles and methods. 1999 Published by International Agency for Research on Cancer, France. ISCN (1995) An International System for Human Cytogenetic Nomenclature. Mitelman F (ed). S Karger, Basel. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129:776-783. Johansson B, Mertens F, Mitelman F. Geographic heterogeneity of neoplasia-associated chromosome aberrations. Genes Chromsom Cancer 1991;3:1-7. Kallmeyer C, Wallmeier M, Kiel K et al. (1998) Decreased numbers of circulating B cells in myeloma patients with reduction after conventional chemotherapy. Am J Hematol 1998;57:287-292. Kaname T, Miyauchi T, Kuwano A, et al. Mapping basigin (BSG), a member of the immunoglobulin superfamily, to 19p13.3. Cytogenet Cell Genet 1993;64:195-197. Katayama I, Yang JPS. Reassessment of a cytochemical test for differential diagnosis of leukemia reticuloendotheliosis. Am J Clin Pathol 1977;68:268-272. Kawano MM, Huang N, Harada H, et al. Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood 1993;82:564-570. Kawano R, Utsunomiya A, Matsuoka H, et al. Registration of hematological disorders by the Kyushu Hematology Organization for Treatment (K-HOT) Study Group. Rinsho Ketsueki 2004;45:478-480. [Article in Japanese] Kaufmann H, Krömer E, Nösslinger T, et al. Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma. Eur J Haematol 2003;71:179-183. Khuder SA, Mutgi AB. Meta-analyses of multiple myeloma and farming. American Journal of Industrial Medicine 1997;32:510-516. Knudsen LM, Hippe E, Hjorth M, et al. Renal function in newly diagnosed multiple myeloma- A demographic study of 1,353 patients. Eur J Haematol 1994;53:207-212. Ko BS, Tang JL, Lee FY, et al. Additional chromosomal abnormalities and variability of BCR breakpoints in Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia in Taiwan. Am J Hematol 2002;71:291-299. Koepsell TD, Daling JR, Weiss NS, et al. Antigenic stimulation and the occurrence of multiple myeloma. Am J Epidemiol 1987;126:1051-1062. Königsberg R, Zojer N, Ackermann J, et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol 2000;18:804-812. Kopantzev E, Roschke V, Rudikoff S. Interleukin-2 mediated modulation of plasma cell tumor growth in a model of multiple myeloma. Hum gene ther 1998;9:13-19. Kumar A, Loughran T, Alsina M, et al. Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol 2003;4:293-304. Kumar S, Anderson KC. Drug insight: thalidomide as a treatment for multiple myeloma. Nature Clinical Practice Oncology. 2005;2:262-270. Kyle RA. History of multiple myeloma. In: Gahrton G, Durie BGM, eds. Multiple myeloma. London.Syndney.Auckland: Arnold, 1996;pp:1-11. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975;50:29-40. Kyle RA, Greipp PR. Plasma cell dyscrasias: current status. Crit Rev Oncol Hematol 1998;8:93-152. Kyle RA, Child JA, Anderson, K, et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-757. Kyle RA, Therneau TM, Rajkumar SV, et al. Incidence of multiple myeloma in Olmsted County, Minnesota-Trend over 6 decades. Cancer 2004a;101:2667-2674. Kyle RA, Steensma DP. History of multiple myeloma. In: Gahrton, G., Durie, B.G.M., Samson, D.M. (eds) Multiple myeloma and related disorders. 2004b. London: Arnold, pp:3-14. Kyoizumi S, Baum CM, Kaneshima H, et al. Implantation and maintenance of functional human bone marrow in SCID-hu mice. Blood 1992;79:1704-1711. Levi F, Te VC, Randimbison L, Vecchia CL. Incidence of multiple myeloma in Olmsten County, Minnesota. Cancer 2005;104:442. (correspondence) Lim HL, Teo CP, Wong K, et al. Multiple myeloma: the National University Hospital (NUH) experience. Singapore Med J 1994;35:371-373. Lin TL, Shih LY, Dunn P, et al. Immuoglobulin D multiple myeloma. Chang Gung Med J (長庚醫誌) 2000;23:451-457. Linet MS, McLaughlin JK, Harlow SD, et al. Family history of autoimmune disorders and cancer in multiple myeloma.Int J Epidemiol 1988;17:512-513. Linet MS, McLaughlin JK, Malker HSR, et al. Occupation and hematopoietic and lymphoproliferative malignancies among women: A linked registry study. JOM 1994;36:1187-1198. Li S, Li H, Zhao X. On the diagnosis of multiple myeloma an analysis of 2,547 domestic cases. Zhonghua Zhong Liu Za Zhi 1995;17:43-46. [Article in Chinese] Liu ZH. Some modern laboratory techniques in clinical hematology. Journal of Formosa Medical Association 1953;52;40-47. Lock RB, Liem N, Farnsworth ML, et al. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood 2002;99:4100-4108. Lolin YI, Chow J, Wickham NWR. Monoclonal gammopathy of unknown significance and malignant paraproteinemia in Hong Kong. Am J Clin Pathol 1996;106:449-456. Ludwig H, Fritz E, Friedl HP. Epidemiologic and age-dependent data on multiple myeloma in Austria. Journal of National Cancer Institute 1982;68:729-733. Lumkul R, Gorin NC, Malehorn MT, et al. Human AML cells in NOD/SCID mice: engraftment potential and gene expression. Leukemia 2002;16:1818-1826. Liu YJ, Mason DY, Johnson GD, et al. Germinal center cells express bcl-2 protein after activation by signals which prevent their entry to apoptosis. Eu J Immunol 1991;21:1905-1910. Liu YJ, Nohnson GD, Gordon J, et al. Germinal centers in T-cell dependent antibody responses. Immunology Today 1992;13:17-21. Ludwig H, Fritz E, Zulian GB, et al. Should alpha-interferon be included as standard treatment in multiple myeloma? Eu J Cancer 1998;34:12-24. Maass G, Schmidt W, Berger M. Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sci USA 1995;92:5540-5544. MacLennan ICM, Gray D. (1986) Antigen-driven selection of virgin and memory B cells. Immunological Reviews 1986;91:61-85. MacLennan ICM, Chan YET. The origin of bone marrow plasma cells. In: Obrams GI, Potter M eds. Epidemiology and biology of multiple myeloma. Berlin: Springer-Verlag, 1991:pp19-35. McKean-Cowdin R, Feigelson HS, Ross RK, et al Declining cancer rates in the 1990s. J Clin Oncol 2000;18:2258-2268. McLaughlin JK, Linet MS, Stone BJ, et al. Multiple myeloma and occupation in Sweden. Archives of Environmental Health 1988;43:7-10. Mellentin JD, Murre C, Donlon TA, et al. The gene for enhancer binding proteins E12/E47 lies at the t(1;19) breakpoint in acute leukemias. Science 1989;246:379-382. Mitelmen F. Geographic heterogeneity of chromosome aberrations in hematologic disorders. Cancer Genet Cytogenet 1986;20:203-208. Miyashita EM, Yang B, Lam KM, et al. A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 1995;80:593-601. Moehler TM, Ho AD, Goldschmidt H, Barlogie B. Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol 2003;45:227-244. Morgan GJ. Advances in the biology and treatment of myeloma. Br J Haematol 1999;105(supplement 1):4-6. Morgan GJ, Davies FE, Linet M. Myeloma aetiology and epidemiology. Biomed Pharmacother 2002;56:223-234. Moulopoulos LA, Gika D, Anagnostopoulos A, et al. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann Oncol 2005;16:1824-1828 Muir, C., Waterhouse, J., Mack, T., et al. (eds) Cancer incidence in five continents, Volume V. IARC Scientific Publication No.88. 1987. Lyon: International Agency for Research on Cancer. Neriishi K, Nakashima E, Suzuki G. Monoclonal gammopathy of undetermined significance in atomic bomb survivors: incidence and transformation to multiple myeloma. Br J Haematol 2003;121:405-410. Ng MH, Wong N, Lau TT, et al. Chromosomal aberrations of multiple myeloma in Chinese patients at diagnosis: a study by combined G-banding and multicolor spectral karyotyping. Oncol Rep 2003;10:587-591. Nilsson T, Höglund M, Lenhoff S, et al. A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences. Br J Haematol 2003;120:960-969. Nishiyama, H., Anderson, R.E., Ishimaru, T., et al. The incidence of malignant lymphoma and multiple myeloma in Hiroshima and Nagasaki atomic bomb survivors. Cancer 1973;32:1301-1309. Olshan AF. Familial and genetic associations. In: Obrams, G.I., Potter, M. (eds) Epidemiology and biology of multiple myeloma. German: Springer-Verlag 1991;pp:31-39. Osterborg A, Yi Q, Henriksson L, et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 1998;91:2459-2466. Ozaki S, Kosaka M, Wakatsuki S, et al. Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24. Blood 1997;90:3179-3186. Phekoo KJ, Schey SA, Richards MA, et al. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol 2004;127:299-304. Pilarksi LM, Belch AR. Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma. Blood 1994;83:724-736. Pilarski LM, Hipperson G, Seeberger K, et al. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 2002a;95:1056-1065. Pilarski LM, Seeberger K, Coupland RW, et al. Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. Exp Hematol 2002b;30:221-228. Pottern LM, Gart JJ, Nam JM, et al. HLA and multiple myeloma among black and white men: evidence of a genetic association. Cancer Epidemiol Biomarkers Prev 1992; 177-182. Pottern LM, Line MS, Devesa SS. Epidemiology of multiple myeloma. In: Wiemik PH, Canellos JP, Dutcher JP, Kyle RA eds. Neoplastic diseases of the blood. New York: Churchill Livigstone 1996:441-452. Rajkumar SV, Fonseca R, Dewald GW, et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet 1999;113:73-77. Rajkumar SV. Kyle RA. Multiple myeloma: diagnosis and treatment. Mayo Clinic Proceedings 2005;80:1371-1382. Rao PH. Comparative genomic hybridization for analysis of changes in DNA copy number in multiple myeloma. Methods in Molecular Medicine 2005;113:71-83. Rasmussen T, Kastrup J, Knudsen LM, et al. High numbers of clonal CD19+ cells in the peripheral blood of a patient with multiple myeloma. Br J Haematol 1999;105:265-267. Rawstron AC, Davies FE, Owen RG, et al. B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors. Br J Haemotol 1998;100:176-183. Reme T, Gueydon E, Jacquet C, et al. Growth and immortalization of human myeloma cells in immunodeficient severe combined immunodeficiency mice: a preclinical model. Brit J Haematol 2001;114:406-413. Rettig MB, Ma HJ, Vescio RA, et al. Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science. 1997;276:1851-1854. Rew SB, Peggs K, Sanjuan I, et al. Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24. Clin Cancer Res 2005;11:3377-3384. Reiman T, Seeberger K, Taylor BJ, et al. Persistent preswitch clonotypic myeloma cells correlate with decreased survival: evidence for isotype switching within the myeloma clone. Blood 2001;98:2791-2799. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617. Riedel DA, Pottern LM. The epidemiology of multiple myeloma. Hematol Oncol Clin North Am 1992;6:225-247. Rigolin GM, Fraulini C, Ciccone M, et al. Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood First Edition Paper, prepublished online November 29, 2005. Robillard N, Pellat-Deceunynck C, Bataille R. Phenotypic characterization of the human myeloma cell growth fraction. Blood 2005;105:4845-4848. Robledo MM, Sanz-Rodriguez F, Hidalgo A, et al. Differential use of very late anigen-4 and –5 integrins by hematopoietic precursors and myeloma cells to adhere to transforming growth factor-β1-treated bone marrow stroma. J Bio Chem 1998;273:12056-12060. Rodon P, Linassier C, Gauvain JB, et al. Multiple myeloma in elderly patients: presenting features and outcome. Eur J Haematol 2001;66:11-17. Roncheti D, Finelli P, Richelda R, et al. Molecular analysis of 11q13 breakpoints in multiple myeloma. Blood 1999;93:1330-1337. Rosenbloom BE, Weinreb NJ, Zimran A, et al. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 2005;105:4569-4572. Ross DD, Yang W, Abruzzo LV, et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 1999;91:429-433. Rusiecki JA, De Roos A, Lee WJ, et al. Cancer incidence among pesticide applicators exposed to atrazine in the agricultural health study. Journal of the National Cancer Institute 2004;96:1375-1382. Sawyer JR, Lukacs JL, Thomas EL, et al. Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. Br J Haematol 2001;112:167-174. Sawyer JR. Multicolor spectral karyotyping in multiple myeloma. Methods in Molecular Medicine 2005;113:49-58. Schwartz, J. Multinational trends in multiple myeloma. Ann NY Acad Sci 1990;609:215-224. Shaughnessy J, Jacobson J, Sawyer J, et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood 2003;101:3849-3856. Shaughnessy Jr. J, Tian E, Sawyer J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol 2003;120:44-52. Shaw CK, Chen LL, Lee A, Lee, TD. Distribution of HLA gene and haplotype frequencies in Taiwan: a comparative study among Min-nan, Hakka, Aborigines and Mainland Chinese. Tissue Antigens 1999;53:51-64. Shen SW, Hu CY, Lin CY, et al. Human leukocyte antigen polymorphisms in the Taiwanese population. J Formos Med Assoc 1999;98:11-18. Shoujing L, Hongran L, Xiangyin Z, et al. On the diagnosis of multiple myeloma an analysis of 2,547 domestic cases. Chun-Hua Chung Liu Tsa Chih (中華腫瘤雜誌) 1995;17:43-46. Shultz LD, Schweitzer PA, Christianson SW, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995;154:180-191. Shimizu K, Nagura E, Takatsuki K. Management of patients with multiple myeloma in Japan: data of 1,383 patients from 16 hospitals and 1 treatment group. Leukemia & Lymphoma 2004;45:2465-2469. Silvestris F, Tucci M, Cafforia P, Dammacco F. Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression. Blood 2001;97:1155-1164. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-1571. Smadja NV, Fruchart C, Isnard F, et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia 1998;12:960-969. Smadja NV, Bastard C, Brigaudeau C, et al. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001;98:2229-2238. Sonneveld P, Lokhorst HM, Vossebeld P. Drug resistance in multiple myeloma. Semi Hematol 1997;34(supple 5):34-39. Sonoda T, Ishida T, Mori M, et al. A case-control study of multiple myeloma in Japan: association with occupational factors. Asian Pac J Cancer Prev 2005;6:33-36. Sonoki T, Hata H, Kuribayashi N, et al. Expression of PRAD1/cyclin D1 in plasma cell malignancy: incidence and prognostic aspects. Br J Haematol 1999;104:614-617. Stewart AK, Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 2005;23:6339-6344. Szczepek AJ, Seeberger K, Wizniak J, et al. A high frequency of circulating B cells share clonotypic Ig heavy chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood 1998;92:2844-2855. Szczepek AJ, Belch AR, Pilarski LM. Expression of IL-6 and IL-6 receptors by circulating clonotypic B cells in multiple myeloma: potential for autocrine and paracrine networks. Exp Hematol 2001;29:1076-1081. Taiwan-Fukien Demographic Fact Book, Ministry of the Interior, R.O.C., 2002. Taniwaki M, Nishida K, Takashima T, et al. Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. Blood 1994;84:2283-2290. Tassone P, Neri P, Carrasco DR, et al. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 2005a;106:713-716. Tassone P, Neri P, Burger R, et al. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin Cancer Res 2005b;11:4251-4258. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483-2494. Tien HF, Wang CH, Lin MT, et al. Correlation of cytogenetic results with immunophenotype, genotype, clinical features and ras mutation in acute myeloid leukemia: a study of 235 Chinese patients in Taiwan. Cancer Genet Cytogenet 1995;84:60-68. Tien HF, Chou CC, Wang CH, et al. Putative normal counterparts of leukaemic cells from CD-7-positive acute myeloid leukaemia can be demonstrated in human haematopoietic tissues. Brit J Haematol 1996;94:501-506. Tricot G, Barlogie B, Jagannath S, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995;86:4250-4256. Tricot GJ. New insights into role of microenvironment in multiple myeloma. Int J Hematol 2002;76(Suppl 1):334-336. Tsunenari T, Koishihara Y, Nakamura A, et al. New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor. Blood 1997;90:2437-2444. Turesson I, Zettervall O, Cuzick J, et al. Comparison trends in the incidence of multiple myeloma in Malmö, Sweden, and other countries, 1950-1979. N Engl J Med 1984;310:421-424. United Nations Statistical Office. (1958) International Standard Industrial Classification of all Economic Activities. New York: United Nations Statistical Office. Urashima M, Chen BP, Chen S, et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 1997;90:754-765. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999;93:3064-3073. Vacca A, Ria R, Ribatti D, et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 2003;88:176-185. Vineis P, Crosignani P, Demicheli V, et al. Incidence and time trends for lymphomas, leukemias and myelomas: hypothesis generation. Leukemia Research 1996;20:285-290. Wang CR, Chuang CY, Lin KT, et al. Monoclonal gammopathies and related autoimmune manifestations in Taiwan. Asian Pac J Allergy Immunol 1992;10:123-128. Wang JX, Boice JD Jr, Li BX, et al. Cancer among medical diagnostic X-ray workers in China. J Natl Cancer Inst 1988;80:344-350. Wang JCY, Lapidot T, Cashman JD, et al. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood 1998;91:2406-2414. Wearne AJ, Joshua DE, Brown RD, et al. Multiple myeloma: the relationship between CALLA-(CD10)-positive lymphocytes in the peripheral blood and light chain isotype suppression. Br J Haematol 1987;67:39-44. Wen YJ, Ling M, Lim SH. Immunogenicity and cross-reactivity with idiotypic IgA of VH CDR3 peptide in multiple myeloma. Br J Haemaol 1998a;100:464-468. Wen YJ, Ling M, Bailey-Wood R, et al. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Can Res 1998b4:957-962. Wendtner CM, Nolte A, Mangold E, et al. Gene transfer of costimulatory molecules B7-1 and B7-2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response. Gene Ther 1997;4:726-735. Xiao J, Messinger Y, Jin J, et al. Signal transduction through the beta 1 integrin family surface adhesion molecules VLA-4 and VLA-5 of human B-cell precursors activates CD19 receptor-associated protein-tyrosine kinases. J Biol Chem 1996;271:7659-7664. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: A model for studying the biology and treatment of myeloma and its manifestations. Blood 1998;92:2908-2913. Yaccoby S, Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 1999;94:3576-3582. Yoshimi I, Kaneko S. Mortality trend of hematologic and lymphatic malignancy (lymphoma, multiple myeloma and leukemia) in Japan: 1960-2000. Jpn J Clin Oncol 2004;34:218-225. Zandecki M, Lai JL, Facon T. Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol 1996;94:217-227. Zhang Z, Vuori K, Reed JC, et al. The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci USA 1995;92:6161-6165.; zh-TW; http://ntur.lib.ntu.edu.tw/handle/246246/55521Test; http://ntur.lib.ntu.edu.tw/bitstream/246246/55521/1/ntu-95-D87421007-1.pdfTest

الإتاحة: http://ntur.lib.ntu.edu.tw/handle/246246/55521Test
http://ntur.lib.ntu.edu.tw/bitstream/246246/55521/1/ntu-95-D87421007-1.pdfTest

المؤلفون: 劉旻昌, Liu, Min-Chang

المساهمون: 許世明, 臺灣大學：病理學研究所

مصطلحات موضوعية: 抑癌基因, 致癌基因, 免疫球蛋白 D, 細胞株, 多發性骨髓瘤, multiple myeloma, immunoglobulin D, cell line, oncogene, tumor suppressor gene

وصف الملف: 551009 bytes; application/pdf

العلاقة: 1.Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ 3rd. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-9. 2.Durie BG. The epidemiology of multiple myeloma. Semin Hematol. 2001;38(2 Suppl 3):1-5. 3.Blade J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol. 1994;12:2398-404. 4.Lin TL, Shih LY, Dunn P, Wang PN, Wu JH, Kao MC. Immunoglobulin D multiple myeloma. Changgeng Yi Xue Za Zhi. 2000;23:451-7. 5.Zandecki M, Lai JL, Facon T. Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol. 1996;94:217-27. 6.Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene. 2001;20:5611-22. 7.Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehl WM. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood. 1996;88:674-81. 8.Motokura T, Arnold A. Cyclin D and oncogenesis. Curr Opin Genet Dev. 1993;3:5-10. 9.Joy Ho P. Chromosomal and genetic abnormalities in myeloma. Clin Lab Haematol. 2002;24(5):259-69. 10.Anderson KC, Lust JA. Role of cytokines in multiple myeloma. Semin Hematol. 1999;36(1 Suppl 3):14-20. 11.Caligaris-Cappio F, Bergui L, Gregoretti MG, Gaidano G, Gaboli M, Schena M, Zallone AZ, Marchisio PC. 'Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood. 1991;77:2688-93. 12.Solary E, Guiguet M, Zeller V, Casasnovas RO, Caillot D, Chavanet P, Guy H, Mack G. Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma. Am J Hematol. 1992;39:163-71. 13.Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, Epstein J. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood. 1994;84:3063-70. 14.Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol. 1995;162:248-55. 15.Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374(Pt 1):1-20. 16.Barbacid M. Ras genes. Annu Rev Biochem. 1987;56:779-827. 17.Ahuja HG, Foti A, Bar-Eli M, Cline MJ. The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood. 1990;75:1684-90. 18.Neri A, Murphy JP, Cro L, Ferrero D, Tarella C, Baldini L, Dalla-Favera R. Ras oncogene mutation in multiple myeloma. J Exp Med. 1989;170:1715-25. 19.Paquette RL, Berenson J, Lichtenstein A, McCormick F, Koeffler HP. Oncogenes in multiple myeloma: point mutation of N-Ras. Oncogene. 1990;5:1659-63. 20.Corradini P, Ladetto M, Voena C, Palumbo A, Inghirami G, Knowles DM, Boccadoro M, Pileri A. Mutational activation of N- and K-Ras oncogenes in plasma cell dyscRasias. Blood. 1993;81:2708-13. 21.Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 1999;13:1899-911. 22.Nunez G, Hockenbery D, McDonnell TJ, Sorensen CM, Korsmeyer SJ. Bcl-2 maintains B cell memory. Nature. 1991;353:71-3. 23.Lee MS, Blick MB, Pathak S, Trujillo JM, Butler JJ, Katz RL, McLaughlin P, Hagemeister FB, Velasquez WS, Goodacre A, et al. The gene located at chromosome 18 band q21 is rearranged in uncultured diffuse lymphomas as well as follicular lymphomas. Blood. 1987;70:90-5. 24.Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL, Korsmeyer SJ. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell. 1985;41:899-906. 25.Pezzella F, Tse AG, Cordell JL, Pulford KA, Gatter KC, Mason DY. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol. 1990;137:225-32. 26.Pettersson M, Jernberg-Wiklund H, Larsson LG, Sundstrom C, Givol I, Tsujimoto Y, Nilsson K. Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood. 1992;79:495-502. 27.Schwarze MM, Hawley RG. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL. Cancer Res. 1995;55:2262-5. 28.Gazitt Y, Fey V, Thomas C, Alvarez R. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells. Int J Oncol. 1998;13:397-405. 29.Tu Y, Xu FH, Liu J, Vescio R, Berenson J, Fady C, Lichtenstein A. Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood. 1996;88:1805-12. 30.Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1992;70:523-6. 31.Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49-53. 32.Portier M, Moles JP, Mazars GR, Jeanteur P, Bataille R, Klein B, Theillet C. p53 and RAS gene mutations in multiple myeloma. Oncogene. 1992;7:2539-43. 33.Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood. 1993;81:128-35. 34.Corradini P, Inghirami G, Astolfi M, Ladetto M, Voena C, Ballerini P, Gu W, Nilsson K, Knowles DM, Boccadoro M, et al. Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia. 1994;8:758-67. 35.Drach J, Ackermann J, Fritz E, Kromer E, Schuster R, Gisslinger H, DeSantis M, Zojer N, Fiegl M, Roka S, Schuster J, Heinz R, Ludwig H, Huber H. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 1998;92:802-9. 36.Avet-Loiseau H, Li JY, Godon C, Morineau N, Daviet A, Harousseau JL, Facon T, Bataille R. P53 deletion is not a frequent event in multiple myeloma. Br J Haematol. 1999;106:717-9. 37.Elnenaei MO, Gruszka-Westwood AM, A'Hernt R, Matutes E, Sirohi B, Powles R, Catovsky D. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A. Haematologica. 2003;88:529-37. 38.Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood. 1995;86:841-54. 39.Liggett WH Jr, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol. 1998;16:1197-206. 40.Ng MH, Chung YF, Lo KW, Wickham NW, Lee JC, Huang DP. Frequent methylation of p16 and p15 genes in multiple myeloma. Blood. 1997;89:2500-6. 41.Seabright M. A rapid banding technique for human chromosomes. Lancet. 1971;2:971-2. 42.Chang FH, Tzeng DS, Lee TM, Chen TC, Hsu LS, Lung FW. Mutations in the p53 tumor suppressor gene in colorectal cancer in Taiwan. Kaohsiung J Med Sci. 2003;19:151-8. 43.Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821-6. 44.Huang SY, Tien HF, Su FH, Hsu SM. Nonirradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma: a potential in vivo culture system. Am J Pathol. 2004;164:747-56. 45.Okuno Y, Takahashi T, Suzuki A, Ichiba S, Nakamura K, Okada T, Okada H, Imura H. In vitro growth pattern of myeloma cells in liquid suspension or semi-solid culture containing interleukin-6. Int J Hematol. 1991;54:41-7. 46.Drexler HG, Matsuo Y. Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia. Leuk Res. 2000;24:681-703. 47.Jobin ME, Fahey JL, Price Z. Long-term establishment of a human plasmacyte cell line derived from a patient with IgD multiple myeloma. I. Requirement of a plasmacyte-stimulating factor for the proliferation of myeloma cells in tissue culture. J Exp Med. 1974;140:494-507. 48.Niho Y, Shibuya T, Yamasaki K, Kimura N. The establishment of a human myeloma cell line elaborating lambda-light chain protein. Int J Cell Cloning. 1984;2:161-72. 49.Namba M, Ohtsuki T, Mori M, Togawa A, Wada H, Sugihara T, Yawata Y, Kimoto T. Establishment of five human myeloma cell lines. In Vitro Cell Dev Biol. 1989;25:723-9. 50.Ishii K, Yamato K, Kubonishi I, Taguchi H, Ohtsuki Y, Miyoshi I. IgD myeloma presenting as a testicular tumor: establishment and characterization of an IgD-secreting myeloma cell line. Am J Hematol. 1992;41:218-24. 51.Matsuo Y, Nakamura S, Adachi T, Tsubota T. Establishment and characterization of new IgD lambda type myeloma cell lines, MOLP-2 and MOLP-3, expressing CD28, CD33 antigens and the IL-6 receptor. Hum Cell. 1993;6:310-3. 52.Ueda C, Yamada H, Akasaka T, Ohmori K, Sasada M, Uchiyama T, Ohno H. Establishment and characterization of a new human myeloma cell line, KYdelta-1, producing the delta/kappa type immunoglobulin. Cancer Genet Cytogenet. 2001;130:42-50. 53.Matsuo Y, Drexler HG, HaRashima A, Okochi A, Hasegawa A, Kojima K, Orita K. Induction of CD28 on the new myeloma cell line MOLP-8 with t(11;14)(q13;q32) expressing delta/lambda type immunoglobulin. Leuk Res. 2004;28:869-77. 54.Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104:607-18. 55.Dewald GW, Kyle RA, Hicks GA, Greipp PR. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood. 1985;66:380-90. 56.Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet. 1995;82:41-9. 57.Konigsberg R, Zojer N, Ackermann J, Kromer E, Kittler H, Fritz E, Kaufmann H, Nosslinger T, Riedl L, Gisslinger H, Jager U, Simonitsch I, Heinz R, Ludwig H, Huber H, Drach J. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol. 2000;18:804-12. 58.Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Hoyer JD, Harrington D, Kay NE, Van Ness B, Greipp PR. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood. 2002;99:3735-41. 59.Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL, Bataille R, Avet-Loiseau H; Intergroupe Francophone du Myelome. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 2002;100:1579-83. 60.Hayashi T, Ohno H, Yamabe H, Nasu K, Miyaoka K, Fujii H, Akaogi T, Konishi H, Maseki N, Akasaka T, et al. Clinical aspects of B-cell malignancy involving the BCL1/PRAD1 locus. Int J Hematol. 1994;59:281-96. 61.Uchimaru K, Taniguchi T, Yoshikawa M, Asano S, Arnold A, Fujita T, Motokura T. Detection of cyclin D1 (bcl-1, PRAD1) overexpression by a simple competitive reverse transcription-polymerase chain reaction assay in t(11;14)(q13;q32)-bearing B-cell malignancies and/or mantle cell lymphoma. Blood. 1997;89:965-74. 62.Troussard X, Avet-Loiseau H, Macro M, Mellerin MP, Malet M, Roussel M, Sola B. Cyclin D1 expression in patients with multiple myeloma. Hematol J. 2000;1:181-5. 63.Soverini S, Cavo M, Cellini C, Terragna C, Zamagni E, Ruggeri D, Testoni N, Tosi P, De Vivo A, Amabile M, Grafone T, Ottaviani E, Giannini B, Cangini D, Bonifazi F, Neri A, Fabris S, Tura S, Baccarani M, Martinelli G. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood. 2003;102:1588-94. 64.Guillerm G, Gyan E, Wolowiec D, Facon T, Avet-Loiseau H, Kuliczkowski K, Bauters F, Fenaux P, Quesnel B. p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood. 2001;98:244-6. 65.Momparler RL, Bovenzi V. DNA methylation and cancer. J Cell Physiol. 2000;183:145-54. 66.Avet-Loiseau H, Garand R, Lode L, Harousseau JL, Bataille R; Intergroupe Francophone du Myelome. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood. 2003;101:1570-1. 67.Avet-Loiseau H, Facon T, Daviet A, Godon C, Rapp MJ, Harousseau JL, Grosbois B, Bataille R. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res. 1999;59:4546-50. 68.Fonseca R, Oken MM, Harrington D, Bailey RJ, Van Wier SA, Henderson KJ, Kay NE, Van Ness B, Greipp PR, Dewald GW. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia. 2001;15:981-6. 69.Gutierrez NC, Hernandez JM, Garcia JL, Almeida J, Mateo G, Gonzalez MI, Hernandez J, Fernandez-Calvo J, San Miguel JF. Correlation between cytogenetic abnormalities and disease characteristics in multiple myeloma: monosomy of chromosome 13 and structural abnormalities of 11q are associated with a high percentage of S-phase plasma cells. Haematologica. 2000;85:1146-52. 70.Kaufmann H, Kromer E, Nosslinger T, Weltermann A, Ackermann J, Reisner R, Bernhart M, Drach J. Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma. Eur J Haematol. 2003;71:179-83. 71.Lauta VM. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer. 2003;97:2440-52. 72.Ogawa M, Nishiura T, Oritani K, Yoshida H, Yoshimura M, Okajima Y, Ishikawa J, Hashimoto K, Matsumura I, Tomiyama Y, Matsuzawa Y. Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line. Cancer Res. 2000;60:4262-9. 73.Moreau P, Harousseau JL, Wijdenes J, Morineau N, Milpied N, Bataille R. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br J Haematol. 2000;109:661-4. 74.Tassone P, Galea E, Forciniti S, Tagliaferri P, Venuta S. The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. Int J Oncol. 2002;21:867-73. 75.Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91:3-21. 76.Kumar G, Gupta S, Wang S, Nel AE. Involvement of Janus kinases, p52shc, Raf-1, and MEK-1 in the IL-6-induced mitogen-activated protein kinase cascade of a growth-responsive B cell line. J Immunol. 1994;153:4436-47. 77.Liu P, Leong T, Quam L, Billadeau D, Kay NE, Greipp P, Kyle RA, Oken MM, Van Ness B. Activating mutations of N- and K-Ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood. 1996;88:2699-706. 78.Billadeau D, Liu P, Jelinek D, Shah N, LeBien TW, Van Ness B. Activating mutations in the N- and K-Ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6. Cancer Res. 1997;57:2268-75. 79.Mazars GR, Portier M, Zhang XG, Jourdan M, Bataille R, Theillet C, Klein B. Mutations of the p53 gene in human myeloma cell lines. Oncogene. 1992;7:1015-8. 80.Iyer R, Ding L, Batchu RB, Naugler S, Shammas MA, Munshi NC. Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma. Leuk Res. 2003;27:73-8. 81.Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81:3382-7. 82.Boccadoro M, Marmont F, Tribalto M, Fossati G, Redoglia V, Battaglio S, Massaia M, Gallamini A, Comotti B, Barbui T, et al. Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis. J Clin Oncol. 1989;7:119-25. 83.Rajkumar SV, Fonseca R, Dewald GW, Therneau TM, Lacy MQ, Kyle RA, Greipp PR, Gertz MA. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet. 1999;113:73-7. 84.Kovacs E. How does interleukin-6 affect the membrane expressions of interleukin-6 receptor and gp130 and the proliferation of the human myeloma cell line OPM-2? Biomed Pharmacother. 2003;57:489-94. 85.Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood. 1992;80:887-90. 86.Ucker DS. Cytotoxic T lymphocytes and glucocorticoids activate an endogenous suicide process in target cells. Nature. 1987;327:62-4. 87.Barlogie B, Epstein J, Selvanayagam P, Alexanian R. Plasma cell myeloma--new biological insights and advances in therapy. Blood. 1989;73:865-79. 88.van de Donk NW, Kamphuis MM, van Dijk M, Borst HP, Bloem AC, Lokhorst HM. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. Leukemia. 2003;17:211-9. 89.Liu Q, Gazitt Y. Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells. Blood. 2003;101:4105-14. 90.Chen YH, Feng XX, Schilder L. Effect of vincristine, adriamycin and glucocorticoids on myeloma cells in vitro. Acta Haematol. 1993;89:61-9.; en-US; http://ntur.lib.ntu.edu.tw/handle/246246/63574Test; http://ntur.lib.ntu.edu.tw/bitstream/246246/63574/1/ntu-93-R89444003-1.pdfTest

الإتاحة: http://ntur.lib.ntu.edu.tw/handle/246246/63574Test
http://ntur.lib.ntu.edu.tw/bitstream/246246/63574/1/ntu-93-R89444003-1.pdfTest

المؤلفون: 莊壽洺

مصطلحات موضوعية: 二多發性骨髓瘤, 染色體, 螢光原位雜交, Multiple myeloma, Chromosome, Fluorescence in situ hybridization

جغرافية الموضوع: 計畫年度：89 第一期, 起迄日期：1999-08-01/2000-07-31

وصف الملف: application/pdf; 749945 bytes

العلاقة: 892314B002056; http://ntur.lib.ntu.edu.tw/handle/246246/25992Test; http://ntur.lib.ntu.edu.tw/bitstream/246246/25992/1/892314B002056.pdfTest

الإتاحة: http://ntur.lib.ntu.edu.tw/handle/246246/25992Test
http://ntur.lib.ntu.edu.tw/bitstream/246246/25992/1/892314B002056.pdfTest

المؤلفون: Huang, Shang-Yi, Lin, Hsiu-Hsia, Lin, Chung-Wu, Li, Chi-Cheng, Yao, Ming, Tang, Jih-Luh, Hou, Hsin-An, Tsay, Woei, Chou, Sheng-Je, Cheng, Chieh-Lung, Tien, Hwei-Fang, 蔡偉, 林中梧, 姚明, 田蕙芬, 黃聖懿, 鄭傑隆, 唐季祿, 侯信安

المساهمون: 臺大醫院-內科部, 臺大醫院-病理部, 臺大醫學院-內科, 臺大醫學院-病理學科暨研究所, Huang, Shang-Yi, Lin, Hsiu-Hsia, Lin, Chung-Wu, Li, Chi-Cheng, Yao, Ming, Tang, Jih-Luh, Hou, Hsin-An, Tsay, Woei, Chou, Sheng-Je, Cheng, Chieh-Lung, Tien, Hwei-Fang, 蔡偉, 林中梧, 姚明, 田蕙芬, 黃聖懿, 鄭傑隆, 唐季祿, 侯信安

مصطلحات موضوعية: soluble PD-L1, bone marrow plasma, multiple myeloma, autologous transplantation, prognosis

الوقت: 136

العلاقة: Oncotarget, 7(38), 62490-62502; http://ntur.lib.ntu.edu.tw/handle/246246/278794Test

الإتاحة: https://doi.org/10.18632/oncotarget.11519Test
http://ntur.lib.ntu.edu.tw/handle/246246/278794Test

المؤلفون: Huang, Shang-Yi, Lin, Chung-Wu, Lin, Hsiu-Hsia, Yao, Ming, Tang, Jih-Luh, Wu, Shang-Ju, Chen, Yao-Chang, Lu, Hsiao-Yun, Hou, Hsin-An, Chen, Chien-Yuan, Chou, Wen-Chien, Tsay, Woei, Chou, Sheng-Je, Tien, Hwei-Fang, 蔡偉, 林中梧, 姚明, 陳建源, 陳耀昌, 田蕙芬, 陳宜君, 黃聖懿, 吳尚儒, 唐季祿, 周文堅, 侯信安

المساهمون: 臺大醫院-內科部, 臺大醫院-病理部, 臺大醫院-檢驗醫學部, Huang, Shang-Yi, Lin, Chung-Wu, Lin, Hsiu-Hsia, Yao, Ming, Tang, Jih-Luh, Wu, Shang-Ju, Chen, Yao-Chang, Lu, Hsiao-Yun, Hou, Hsin-An, Chen, Chien-Yuan, Chou, Wen-Chien, Tsay, Woei, Chou, Sheng-Je, Tien, Hwei-Fang, 蔡偉, 林中梧, 姚明, 陳建源, 陳耀昌, 田蕙芬, 陳宜君, 黃聖懿, 吳尚儒, 唐季祿, 周文堅, 侯信安

مصطلحات موضوعية: Cereblon, Immunohistochemistry, Immunomodulatory drugs, Multiple myeloma, Prognosis

الوقت: 136

العلاقة: Ann. Hematol., 93(8), 1371-1380; http://ntur.lib.ntu.edu.tw/handle/246246/278552Test

الإتاحة: https://doi.org/10.1007/s00277-014-2063-7Test
http://ntur.lib.ntu.edu.tw/handle/246246/278552Test

المؤلفون: 賴建榮, 鍾旭東, 戴槐青, 黃聖懿, 張逸良, 闕世傑, LAI, CHIEN-RONG, CHUNG, SHIU-DONG, TAI, HUAI-CHING, HUANG, SHANG-YI, CHANG, YIH-LEONG, CHUEH, SHIH- CHIEH, CHUEH, SHIH-CHIEH

المساهمون: 泌尿部

مصطلحات موضوعية: multiple myeloma, plasmacytoma, radiation, tumor excision

العلاقة: SOUTHERN MEDICAL JOURNAL v.103 n.8 pp.831-833; http://ntur.lib.ntu.edu.tw/handle/246246/234339Test

الإتاحة: http://ntur.lib.ntu.edu.tw/handle/246246/234339Test

المؤلفون: 林琬琬, LIN, WAN-WAN

المساهمون: 藥理學科所

مصطلحات موضوعية: NF-KAPPA-B, TUMOR-NECROSIS-FACTOR, TOLL-LIKE RECEPTORS, TGF-BETA, COLON-CANCER, MULTIPLE-MYELOMA

العلاقة: JOURNAL OF CLINICAL INVESTIGATION v.117 n.5 pp.1175-1183; http://ntur.lib.ntu.edu.tw/handle/246246/89709Test

الإتاحة: http://ntur.lib.ntu.edu.tw/handle/246246/89709Test

المؤلفون: 吳振漢, 陳世乾, 謝汝敦, 陳淳, 張宏江, WU, WILFRED-C-H, CHEN, SHYH-CHYAN, HSIEH, JU-TON, CHEN, JUN, CHANG, HONG-CHIANG

المساهمون: 泌尿科

مصطلحات موضوعية: antibody, genitourinary, multiple myeloma, mycobacterium

العلاقة: JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION v.105 n.9 pp.753-755; http://ntur.lib.ntu.edu.tw/handle/246246/94239Test

الإتاحة: http://ntur.lib.ntu.edu.tw/handle/246246/94239Test